COPD Exacerbation Modelling Using Unobtrusive Sensors - the TOLIFE Clinical Study A

Exclusion Criteria

• •Occurrence of any of the following within three months before informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD).
• •Uncontrolled congestive heart disease (NYHA class \>3).
• •Having undergone major lung surgery (e.g., lung transplant)
• •Primary respiratory diseases other than COPD.
• •Participant who has experienced a major respiratory infection or exacerbation within 2 weeks before screening
• •Lung volume reduction within six months before screening.
• •Active treatment for cancer or other malignant diseases that in the opinion of the investigator, have an impact on the patient's quality of life such as to prevent adherence to the study.
• •Acute psychosis or major psychiatric disorders or continued substance abuse.
• •Severe disease that limits survival to 1 year.
• •Patients with severe cognitive impairment (MMSE \< 18).
• •Substantial limitations in mobility due to factors other than COPD.
• •Inability to follow the study procedures (e.g., due to language problems, psychological disorders) or unable to read, understand and fill in a questionnaire.